
In spite of GLP-1 sales increasing overall, Novo Nordisk's diabetes tablet Rybelsus sold for significantly less than what industry analysts had forecast for the first three months of the year.
Based on estimates gathered by Novo Nordisk from around 28 analysts before the publication of the report, Rybelsus was predicted to surpass DKK 1bn sales in this year's first quarter.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app